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Endocannabinoids participate in the control of neurogenesis, neural cell death and gliosis.
The pharmacological effect of the fatty acid amide hydrolase (FAAH) inhibitor URB597,
which limits the endocannabinoid degradation, was investigated in the present study.
Cell proliferation (phospho-H3+ or BrdU+ cells) of the main adult neurogenic zones as
well as apoptosis (cleaved caspase-3+), astroglia (GFAP+), and microglia (Iba1+ cells)
were analyzed in the hippocampus, hypothalamus and striatum of rats intraperitoneally
treatedwith URB597 (0.3mg/kg/day) at one dose/4-days resting or 5 doses (1 dose/day).
Repeated URB597 treatment increased the plasma levels of the N-acylethanolamines
oleoylethanolamide, palmitoylethanolamide and arachidonoylethanolamine, reduced the
plasma levels of glucose, triglycerides and cholesterol, and induced a transitory body
weight decrease. The hippocampi of repeated URB597-treated rats showed a reduced
number of phospho-H3+ and BrdU+ subgranular cells as well as GFAP+, Iba1+
and cleaved caspase-3+ cells, which was accompanied with decreased hippocampal
expression of the cannabinoid CB1 receptor gene Cnr1 and Faah. In the hypothalami of
these rats, the number of phospho-H3+, GFAP+ and 3-weeks-old BrdU+ cells was
specifically decreased. The reduced striatal expression of CB1 receptor in repeated
URB597-treated rats was only associated with a reduced apoptosis. In contrast, the
striatum of acute URB597-treated rats showed an increased number of subventricular
proliferative, astroglial and apoptotic cells, which was accompanied with increased
Faah expression. Main results indicated that FAAH inhibitor URB597 decreased neural
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proliferation, glia and apoptosis in a brain region-dependent manner, which were coupled
to local changes in Faah and/or Cnr1 expression and a negative energy context.
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Introduction
The endocannabinoids participate in a variety of biological
activities in the central nervous system, including synaptic
communication, neurogenesis (proliferation, differentiation and
survival), neuroinflamation and pain perception as a conse-
quence of a neuroprotective response on demand after dam-
age (Stella, 2010; Katona and Freund, 2012; Galve-Roperh et al.,
2013; Bandiera et al., 2014). The N-acylethanolamines (NAEs),
such as arachidonoylethanolamine (AEA), oleoylethanolamine
(OEA) and palmitoylethanolamine (PEA), likely belong to inde-
pendent signaling pathways, including synthesis (NAPE-PLD,
PLC, PTPN22, Abh4), inactivation (FAAH, NAAA, COX-2) and
cannabinoid (CB1, CB2) and non-cannabinoid (PPARs, GPR55,
TRPV1) receptors (Cravatt and Lichtman, 2002; Liu et al., 2006;
Mackie and Stella, 2006; Simon and Cravatt, 2006; Yates and
Barker, 2009; Ueda et al., 2010). The effectiveness of these
endocannabinoids in promoting a specific biological process
changes depending on the affinity to their receptors (Pertwee,
2008). Thus, EC50 values of AEA are 18, 31, and 27 nM at
GPR55, CB1, and CB2 respectively (Devane et al., 1992; Lam-
bert et al., 1999; Ryberg et al., 2007), EC50 values of OEA are
0.12, 0.44, >30 and >30µM at PPARα, GPR55, CB1 and CB2
respectively (Rodríguez de Fonseca et al., 2001), and EC50 val-
ues of PEA are 0.004, 3, 19.8, and >30µM at GPR55, PPARα,
CB1 and CB2 respectively (Lambert et al., 2001, 2002). The dis-
tinct receptor affinity and activation by NAEs signaling can lead
to a variety of responses including opposite biological effects. For
instance, AEA enhances food intake and energy storage (Jamshidi
and Taylor, 2001; Kirkham et al., 2002; Aronne and Thornton-
Jones, 2007; Cota, 2008). The activation of CB1 receptors in the
paraventricular hypothalamic nucleus and nucleus accumbens
increases appetite and eating motivation, respectively (Jamshidi
and Taylor, 2001; Kirkham et al., 2002). On the contrary, OEA
binds to PPARα to reduce food intake and promote lipolysis (Fu
et al., 2003). OEA produces anorexic effects by activating satiety
signals forwarded from the vagal afferent neurons to the paraven-
tricular hypothalamic nucleus (Lo Verme et al., 2005a). Contrary
to the previous hypothesis, NAEs are able to produce similar
Abbreviations: 3v, third ventricle; ARC, arcuate nucleus of hypothalamus; BrdU,
5-bromo-2′-deoxyuridine; CA1/3, field 1/3 of Cornu Ammonis; CB1/2, cannabi-
noid type 1 and 2 receptor; Cnr1, cannabinoid CB1 receptor gene; DG, dentate
gyrus; EPl, external plexiform layer; gcl, dentate granular cell layer; GrO, gran-
ular cell layer of the olfactory bulb; FAAH, fatty acid amide hydrolase; GFAP,
glial fibrillary acidic protein; HOMA-IR/β, homeostatic model assessment, insulin
resistance/β-cell function; ml, molecular layer; Iba-1, ionized calcium-binding
adapter molecule 1; IPl, internal plexiform layer; lv, lateral ventricle; NeuN, hexari-
bonucleotide binding protein-3; pcl, polymorphic cell layer; PVH, paraventricular
nucleus of hypothalamus; SGZ, subgranular zone of dentate gyrus; Str, striatum;
SVZ, subventricular zone of the lateral ventricles; SL-M, stratum lacunosum-
moleculare; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum;
URB597, cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester; VMH, ven-
tromedial nucleus of hypothalamus.
biological effects through independent signaling pathways. For
instance, both AEA and PEA, targeting to CB1/CB2/TRPV1 and
PPARα respectively, can block neuroinflammation by regulating
glia migration and survival (Walter et al., 2003; Lo Verme et al.,
2005b; Stella, 2010; Stock et al., 2012).
The hydrolyzing NAEs enzyme fatty acid amide hydrolase
(FAAH) is expressed in the brain with particularly high levels
in the hippocampus and low levels in the hypothalamus (Kano
et al., 2009). Moreover, FAAH has different catalytic proper-
ties depending on substrate specificity, cell type and physiolog-
ical conditions (Sun et al., 2005). Despite OEA and PEA are
10 times more abundant than AEA in the brain (Cadas et al.,
1997), FAAH preferentially hydrolyzes AEA over OEA and PEA
(Ueda et al., 2000). The FAAH inhibitor URB597 (KDS-4103)
selectively blocks AEA hydrolysis in neurons without having any
inhibitory effect on AEA transport (Kathuria et al., 2003; Piomelli
et al., 2006). In rats, at an intraperitoneal dose of 0.3mg/kg,
URB597 is rapid in onset (<15min), persistent (>12 h) and
accompanied by elevations of NAEs in the brain and periph-
eral tissues (Fegley et al., 2005). Regarding behavior activity,
URB597 evoked anxiolytic, antidepressant and antinociceptive-
like responses (Clapper et al., 2009; Gaetani et al., 2009; Lomazzo
et al., 2015). Through URB597 at a dose of 0.3mg/kg, it maxi-
mally blocks FAAH activity and increases brain levels of AEA, but
does not reproduce the spectrum of pharmacological responses
that characterize AEA such as catalepsy, hypothermia or hyper-
phagia, three typical signs of CB1 activation (Kathuria et al.,
2003). Furthermore, URB597 was found to promote CB2 antag-
onist SR144528-sensitive anti-inflammatory effects (Holt et al.,
2005), for instance, by decreasing microglial activation in the
brain (Murphy et al., 2012; Slusar et al., 2013).
Both CB1 and CB2 receptors can modulate neurogenesis
and/or gliogenesis (Aguado et al., 2006; Molina-Holgado et al.,
2007; Goncalves et al., 2008; Rivera et al., 2011). CB1 and CB2
activation and FAAH inhibition increased neural proliferation,
an action that can be abrogated in CB1-deficient mouse neuro-
spheres and confirmed in the brains of FAAH-deficient mouse
embryos (Aguado et al., 2005; Goncalves et al., 2008). More-
over, CB1 activation does not only protect neurons from brain
injury (Mechoulam et al., 2002; Parmentier-Batteur et al., 2002;
Marsicano et al., 2003), but also protects astrocytes from apop-
tosis, promotes astroglial proliferation and differentiation, and
prevents oligodendrocyte cell death in vitro (Aguado et al., 2006;
Fernández-Ruiz et al., 2007; Gomez et al., 2011). Interestingly,
these effects can be partially reversed by TRPV1 antagonist
(Cohen-Yeshurun et al., 2013).
Taken together, the evidence suggests that brain processes
such as neurogenesis and neuroprotection can be regulated
depending on the endocannabinoid levels and the activation of
their local targets. We hypothesized that the FAAH inhibitor
URB597 can influence neural proliferation, cell survival and
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inflammation as a consequence of alterations in the endocannabi-
noid tone. To this end, we analyzed the cell proliferation and
survival in the principal neurogenic zones of the adult rat brain,
including the subgranular zone (SGZ) of the dentate gyrus and
the subventricular zone (SVZ) of the lateral ventricles, as well as
the astroglial, microglial and apoptotic cells in the hippocampus,
hypothalamus and striatum of lean rats after the administration
of one dose/4-days resting or 5 doses (1 dose/day) of URB597
at an effective dose of 0.3mg/kg/day. Results were interpreted
regarding the energy balance, the plasma levels of OEA, PEA and
AEA, and the hippocampal, hypothalamic and striatal expression
of FAAH and CB1 receptor.
Materials and Methods
Ethics Statement
The protocols for animal care and use were approved by the
Ethics and Research Committee at the Hospital Universitario
Regional de Málaga and Universidad de Málaga. All experimen-
tal animal procedures were carried out in strict accordance with
the European Communities directive 86/609/ECC (24 November
1986) and Spanish legislation (BOE 252/34367-91, 2005) regulat-
ing animal research. All efforts were made to minimize animal
suffering and to reduce the number of animals used.
Animals
Male Wistar rats (approximately 250 g, 10–12 weeks old; Charles
Rivers, Barcelona, Spain) were housed individually in cages
maintained in standard conditions (Servicio de Estabulario,
Facultad de Medicina, Universidad de Málaga) at 20 ± 2◦C
room temperature, 40 ± 5% relative humidity and a 12-h
light/dark cycle with dawn/dusk effect. Water and standard
rodent chow (Prolab RMH 2500, 2.9 kcal/g) were available ad
libitum, unless otherwise indicated for specific experimental
procedures.
Habituation
The animals were daily weighed, handled for 10min and habitu-
ated to injection procedures (holding and pseudo-injection) dur-
ing 1 week before the experimentation in order tominimize stress
effects. To further habituate the animals to feeding procedures,
84 h before testing with drug, the animals were food deprived for
24 h with ad libitum access to water. Then, the rats were main-
tained under free-feeding period for 48 h. After this time, the
animals were definitively food-deprived for 12 h (with free access
to water) before the beginning of the food exposure and treat-
ment. Finally, a can with a measured amount of food (usually
50–60 g per day) and a bottle containing 250ml of fresh water
were placed in the cage at time 0. Food pellets and rats were
periodically weighed.
Administrations of URB597
Fatty acid amide hydrolase (FAAH) inhibitor URB597 (cyclo-
hexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester; Cayman
Chemical, cat. no. 10046, Ann Arbor, MI, USA) was dissolved
in a vehicle containing 33% (v/v) DMSO in sterile 0.9% NaCl
solution, just before each experiment. The vehicle or URB597
were intraperitoneally (i.p.) injected in a final volume of 1ml/kg
body weight. The optimal dose at which acute treatment would be
more effective was selected for the repeated treatment experiment
(see Supplementary Materials and Figure S1). Thus, URB597 was
acutely or repeatedly administrated at a dose of 0.3mg/kg body
weight for 5 consecutive days at intervals of 24 h (08:00 a.m.).
During the repeated administration of URB597, the cumulative
food intake and body weight gain were daily measured for the 5
days of treatment. In a first batch, the animals were sacrificed 2 h
after the last injection of vehicle or URB597. Finally, we generated
three experimental groups (n = 16/group): (1) Vehicle adminis-
tration for 5 days (vehicle group); (2) One URB597 administra-
tion (0.3mg/kg/day) and repeated vehicle administration for the
remaining 4 days (acute URB597 group); (3) Repeated URB597
administration (0.3mg/kg/day) for 5 days (repeated URB597
group) (Figure S2). In a second batch, the animals were sacri-
ficed 3 weeks after the last treatment day. We generated two
experimental groups (n = 8/group): (1) Vehicle administra-
tion for 5 days (vehicle group); (2) Repeated URB597 admin-
istration (0.3mg/kg/day) for 5 days (repeated URB597 group)
(Figure S2).
BrdU Administration
5′-bromo-2′-deoxyuridine (BrdU, cat. no. B5002, Sigma, St.
Louis, MO, USA) was dissolved at 15 mg/mL in sterile 0.9%
NaCl solution, and i.p. administrated at a dose of 50mg/kg body
weight twice per day at intervals of 10 h (08:00, 18:00 h), for 4
consecutive days (Cifuentes et al., 2011).
Sample Collection
Previous to sacrifice, all animals were anaesthetized (sodium
pentobarbital, 50mg/kg body weight, i.p.) 2 h or 3 weeks after
the last dose of treatment in a room separate from the other
experimental animals. Most blood samples (n = 12/group)
were briefly collected into tubes containing EDTA-2Na (1mg/ml
blood) and centrifuged (1600 g for 10min, 4◦C). Plasma sam-
ples were then frozen and stored at −80◦C for biochemical,
hormonal and liquid chromatography–mass spectrometry anal-
yses. Half of the first batch of animals (n = 8/group) were
sacrificed by decapitation and their brains were collected, quick
frozen and stored at−80◦C. These brains were then prepared on
dry ice to obtain sections of 1mm thick by using razor blades
and a rat brain slicer matrix. The hippocampus, hypothalamus
and striatum were precisely removed from −2.16 to −4.20 and
from 2.28 to −0.24 Bregma levels (Paxinos and Watson, 2007)
with fine surgical instruments. Brain samples were weighed and
stored at −80◦C until they were used for RT-qPCR and liq-
uid chromatography–mass spectrometry analyses. Another half
of the first batch of animals and the second batch of animales
(n = 8/group) were transcardially perfused with 4% formalde-
hyde in 0.1M phosphate buffer (PB) and the brains were dis-
sected out and kept in the same fixative solution overnight
at 4◦C. The brains were then cut into 30-µm-thick coronal
sections and were divided in eight parallel series by using a
vibratome (Leica VT1000S). Sections were stored at 4◦C in
PB with 0.002% (w/v) sodium azide until they were used for
immunostaining.
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Immunohistochemistry
The brain sections were divided in eight parallel series. Each par-
allel series consisted of one coronal section for each 240µm.
Free-floating coronal sections from −2.16 to −4.20 Bregma lev-
els (hippocampus and hypothalamus), from Bregma 2.28 to -
0.24 Bregma levels (striatum) and from 7.60 to 6.60 Begma
levels (olfactory bulbs) of each parallel series were selected for
each immunohistochemistry. Sections were incubated overnight
in the following diluted primary antibody at 4◦C: rabbit anti-
FAAH (1:200, Cayman, cat no. 101600; Gulyas et al., 2004), rab-
bit anti-CB1 (1:200, Frontier Institute, cat. no. CB1-Rb-Af380-1;
Uchigashima et al., 2007), rabbit anti-phospho-histone H3
(Ser10) (2µg/ml, Upstate, cat. no. 06-570), mouse anti-BrdU
(1:2000, Hybridoma Bank, Iowa City, IA, USA; ref. G3G4), rab-
bit anti-cleaved caspase-3 (1:500, Cell Signaling; cat. no. 9661),
mouse anti-glial fibrillaric acidic protein (GFAP) (1:500, Sigma,
cat. no. G3893) and rabbit anti-Iba-1 (1:1000, Wako, cat. no.
019-19741) (Cifuentes et al., 2011; Rivera et al., 2011, 2013). The
following day the sections were incubated in the respective sec-
ondary antibody for 90min: biotinylated goat anti-mouse IgG
(1:500, Sigma; cat. no. B7264) or biotinylated donkey anti-rabbit
IgG (1:500, Amersham, Little Chalfont, England; cat. no. RPN
1004). The sections were then incubated in ExtrAvidin peroxi-
dase (Sigma, St. Louis, MO) diluted 1:2000 in darkness at room
temperature for 1 h. Finally, immunolabeling was revealed with
0.05% diaminobenzidine (DAB; Sigma), 0.05% nickel ammo-
nium sulfate and 0.03% H2O2 in PBS. Brain sections from the
second batch of animals were only used to check cell survival by
BrdU immunohistochemistry.
Double Immunofluorescence
The following antibodies were used: rat anti-BrdU (1:2000;
Accurate Chemical and Scientific, Westbury, NY, USA, cat.
no. OBT0030G), mouse anti-NeuN (1:500; Millipore, cat. no.
MAB377), mouse anti-β3 tubulin (1:5000; Promega, Madison,
WI, USA) and mouse anti-GFAP (1:500; Sigma, cat. no. G3893).
Sections were incubated overnight at 4◦C with a cocktail of the
primary antibodies. The rat anti-BrdUwas detected with the don-
key anti-rat IgG (H+L) labeled with Alexa Fluor R© 488 (1:1000;
Molecular Probes, Invitrogen, Paisley, UK, cat. no. A21208).
The antibodies NeuN, β3-tubulin and GFAP were detected
with the donkey anti-mouse IgG (H+L) labeled with Alexa
Fluor R© 594 (1:1000; Molecular Probes, cat. no. A21203). The
sections labeled by double immunofluorescence (BrdU+NeuN,
BrdU+β3-tubulin or BrdU+GFAP) were visualized with a con-
focal laser (spectral) scanning microscope (Leica TCS NT; Leica
Microsystems) equipped with a 561 nm DPM laser (argon 30%)
and a 40× objective (HCX PL APO CS 40.0x1.25 OIL UV).
The emission filter settings were 500–550 nm for PMT2 (green)
and 610–700 nm for PMT3 (red). Depending on the level of
zoom used in each image, the XY voxel size was from 100 to
77 nm, approximately. Settings of light and brightness/contrast
were adjusted by using the Leica LAS AF Lite imaging software.
Cell Counting
Phospho-H3, BrdU, GFAP, Iba-1 and cleaved caspase 3-
immunoreactive (-ir) nuclei and cells that came into focus
were manually counted from Bregma −2.16 to −4.20mm at
hippocampal and hypothalamic levels, from Bregma 2.28 to
−0.24mm at striatal levels and from Begma 7.60 to 6.60mm
at olfactory bulb levels (Paxinos and Watson, 2007). Represen-
tative counting frames were evaluated using a standard optical
microscope with the 40× objective (Nikon Instruments Europe
B.V., Amstelveen, TheNetherlands) coupled to theNIS-Elements
Imaging Software 3.00 (Nikon). Focusing in the hippocampus,
phospho-H3 and BrdU-ir nucleus counts were performed in the
subgranular zone (SGZ) of the dentate gyrus (DG), while sur-
vived BrdU-ir nucleus counts and GFAP, Iba-1 and cleaved cas-
pase 3-ir cell counts were carried out in the whole hippocampus
(DG, CA3 and CA1 areas). Focusing in the hypothalamus, count-
ing was performed in the paraventricular (PVH), ventromedial
(VMH) and arcuate (ARC) nuclei and median eminence. Focus-
ing in the striatum, phospho-H3 and BrdU-ir nucleus counts
were performed in the subventricular zone (SVZ) of the lateral
ventricles, while survived BrdU-ir nucleus counts and GFAP, Iba-
1 and cleaved caspase 3-ir cell counts were carried out in the
whole striatum. Survived BrdU-ir nucleus counts were also per-
formed in the olfactory bulbs. Immunostained cells located in the
uppermost side that came into focus while moving down through
the thickness of the section were counted. Overall, quantification
was expressed as the average number of cells per area (mm2) for
each experimental group.
Quantification of Immunoreactivity
Densitometric analysis of the GFAP, FAAH, and CB1 immunore-
activity was evaluated in the three hippocampal areas (dentate
gyrus, CA3 and CA1) and hypothalamus from Bregma −2.16
to−4.20mm, and in the striatum fromBregma 2.28 to−0.24mm
(Paxinos and Watson, 2007). Digital high-resolution micropho-
tographs of representative areas were taken with a 10× objective
under the same conditions of light and brightness/contrast with
an Olympus BX41 microscope equipped with an Olympus DP70
digital camera. Quantification was determined using the anal-
ysis software ImageJ 1.38X (NIH, USA). Focusing in CA1 and
CA3 areas, we considered the following layers: stratum oriens
(SO), stratum pyramidale (SP), stratum radiatum (SR), stratum
lucidum (SL) and stratum lacunosum-moleculare (SL-M). For
dentate gyrus, we considered the molecular layer (ml), the gran-
ular cell layer (gcl) and the polymorphic cell layer (pcl). Focus-
ing in the hypothalamus, densitometry were performed in the
paraventricular (PVH), ventromedial (VMH) and arcuate (ARC)
nuclei and median eminence.
RNA Isolation and RT-qPCR Analysis
We performed real-time PCR (TaqMan, Applied Biosystem,
Carlbad, CA, USA) as described previously (Crespillo et al., 2011;
Decara et al., 2012) using specific sets of primer probes (Faah:
Rn00577086_m1, Amplicon length: 63; Cnr1: Rn02758689_s1,
Amplicon length: 92; Actb: Rn00667869_m1, Amplicon length:
91; Life Technologies). Briefly, brain regions were homogenized
on ice and RNAwas extracted following Trizol R© method accord-
ing to the manufacture’s instruction (Gibco BRL Life Technolo-
gies, Baltimore, MD, USA). RNA samples were isolated with
RNAeasy minelute cleanup-kit including digestion with DNase
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I column (Qiagen, Hilden, Germany). After reverse transcript
reaction from 1µg of mRNA, quantitative real-time reverse tran-
scription polymerase chain reaction (qPCR) was performed in a
CFX96TMReal-Time PCRDetection System (Bio-Rad, Hercules,
CA, USA) and the FAM dye label format for the TaqMan R© Gene
Expression Assays (Applied Biosystem). Melting curve analysis
was performed to ensure that only a single product was ampli-
fied. After analyzing several control genes, values obtained from
the brain samples were normalized in relation to β-actin (Actb)
levels.
Endocannabinoid Quantification
The determination of AEA, PEA, OEA, and 2-arachidonoyl glyc-
erol (2-AG) was done as previously described (Pastor et al., 2014).
Briefly, aliquots of 175µL of plasma were spiked with AEA-d4,
PEA-d4, OEA-d4, and 2-AG-d5 (Cayman Chemical, Ann Har-
bor,MI), diluted up to 1mLwith 0.1M ammonium acetate pH 4.0
(Merck, Darmstadt, Germany), extracted with tert-butyl-methyl-
ether (Merck) and analyzed by LC/MS-MS on a triple quadrupole
mass spectrometer (Agilent 6410, Wilmington, DE) that oper-
ated with an electrospray ionization source (ESI) on the positive
mode. Chromatographic separation was done with aWaters C18-
CSH column (3.1 × 100mm × 1.8µm particle size), detection
was done by selected reaction monitoring (SRM) and quantifica-
tion was done by isotope dilution. 2-MGs were reported as the
sum of isomer 1 and isomer 2 due to the instability of isomer 2 to
isomerization.
Biochemical and Hormonal Analysis
Glucose, triglycerides, total cholesterol, high-density lipoprotein
(HDL)-cholesterol, creatinine, urea, uric acid and the hepatic
enzymes aspartate transaminase (AST) and alanine transami-
nase (ALT) were analyzed using commercial kits according to
the manufacturer’s instructions in a Hitachi 737 Automatic Ana-
lyzer (Hitachi Ltd., Tokyo, Japan). Plasma levels of IGF-1, insulin,
leptin and adiponectin were determined with three different
enzyme-linked immunosorbent assay (ELISA) kits from BioVen-
dor (Modrice, Czech Republic), Mercodia AB (Uppsala, Sweden)
and B-Bridge International, Inc. (Mountain View, CA, USA),
respectively. To perform the ELISA protocols in rat samples, we
used 50, 25, 100, 100µl of plasma to determine the concentra-
tions of IGF-1, insulin, leptin, adiponectin, respectively. In all
cases, a calibration curve and internal controls were included in
each assay.
Statistical Analysis
Statistical analysis of the results was performed using the com-
puter program GraphPad Prism version 5.04 (GraphPad Soft-
ware Inc., San Diego, CA, USA). Data were represented as the
mean ± s.e.m. for at least six determinations per experimental
group. Kolmogorov-Smirnov normality tests indicated that all
data followed a Gaussian distribution (P > 0.1), so we selected
a parametric statistical test. Statistical analysis was performed
using one or Two-Way ANOVA and Bonferroni’s test or Stu-
dent’s t-test when appropriate. P < 0.05 was considered to be
significant.
FIGURE 1 | Effect of acute and repeated treatment of URB595
(0.3mg/kg) on cumulative food intake (A) and body weight gain (B). The
histograms represents the mean ± s.e.m. (n = 8) per experimental group.
ANOVA and Bonferroni’s test: *P < 0.05 vs. vehicle group.
Results
Metabolic Status of the Rats Treated with
URB597
We analyzed the effect of URB597 on food intake and body
weight gain for 5 days (Figure 1). After Two-Way ANOVA
analysis, a treatment effect on body weight gain was observed
[F(2, 84) = 5.89, P = 0.004]. Moreover, the effect of the repeated
treatment on body weight gain showed a higher significance
[F(1, 56) = 10.7, P = 0.001] than that of the acute treat-
ment [F(1, 56) = 5.82, P = 0.019]. As a consequence, repeated
URB597-treated rats showed a decrease in their body weight gain
up to 48 and 72 h after the beginning of the repeated treatment
when they were compared with vehicle-treated rats (∗P < 0.05)
(Figure 1B). Moreover, a transitory decrease in the body weight
gain was also observed in the second day after acute treatment of
URB597.
Biochemical and Hormonal Profile of the Rats
Treated with URB597
To better understand themetabolic context associated toURB597
treatment, we evaluated the biochemical and hormonal pro-
file in the plasma of these rats (Table 1). Biochemical param-
eters included basal glucose, triglycerides, total cholesterol,
high-density lipoprotein (HDL)-cholesterol, creatinine, urea,
uric acid and aspartate transaminase (AST)/alanine transam-
inase (ALT) ratio. Metabolic hormones included insulin, lep-
tin, adiponectin and IGF-1. The plasma of rats acutely and
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TABLE 1 | Effect of URB597 on plasma metabolites and hormonesa.
Vehicle URB597 URB597
(acute) (repeated)
Glucose (md/dL) 165.8± 7.1 131.8±13.8* 131.9±9.5*
Triglycerides (mg/dL) 153.0± 22.2 88.0±4.2* 101.6±11.6*
Total cholesterol (mg/dL) 87.6± 2.5 78.0±2.2* 78.7±2.2*
HDL-cholesterol (mg/dL) 27.0± 0.4 24.6±0.6** 24.8±1.1*
Creatinine (mg/dL) 0.56± 0.01 0.58±0.02 0.56±0.02
Urea (mg/dL) 37.2± 0.8 33.1±1.1* 33.5±1.09*
Uric acid (mg/dL) 0.63± 0.03 0.70±0.03 0.66±0.02
AST/ALT ratio 0.35± 0.05 0.34±0.05 0.18±0.02**##
Insulin (ng/mL) 4.62± 1.03 2.7±0.79 1.43±0.37**
HOMA-IR (a.u.) 41.3± 9.2 17.8±4.6* 10.1±2.5**
HOMA-β (a.u.) 254.7± 25.1 485.5±64.7** 515.5±68.1**
Leptin (pg/mL) 4130± 269 4219±177 2393±147***
Adiponectin (ng/mL) 7168± 561 8864±551 6763±834
IGF-1 (ng/mL) 1285± 37 1270±37 1268±67
aLevels of plasma metabolites and metabolic hormones in rats acutely (one dose/4-days
resting) and repeatedly (5 doses) treated with URB597 (0.3mg/kg). Values represent the
mean ± s.e.m. (n = 6). One-way ANOVA: *P < 0.05, **P < 0.01, ***P < 0.001 vs. rats
treated with vehicle; ##P < 0.05 vs. rats acutely treated with URB597.
repeatedly treated with URB597 showed lower levels of basal glu-
cose [F(2, 15) = 5.95,
∗P < 0.05], triglycerides [F(2, 15) = 6.69,
∗P < 0.05], total cholesterol [F(2, 15) = 6.29,
∗P < 0.05],
HDL-cholesterol [F(2, 15) = 5.21,
∗∗P < 0.01 and ∗P < 0.05,
respectively] and urea [F(2, 15) = 5.22,
∗P < 0.05] (Table 1).
The AST/ALT ratio, used as diagnostic marker for liver damage,
was lower in the plasma of repeated URB597-treated rats than
that of vehicle or acute URB597-treated rats [F(2, 15) = 7.13,
∗∗/##P < 0.01]. URB597 didn’t induce any change in the plasma
levels of uric acid. Regarding insulin, we observed a decrease
in the plasma levels of the rats repeatedly treated with URB597
[F(2, 15) = 5.03,
∗∗P < 0.01]. The decrease of both basal glu-
cose and insulin levels in plasma resulted in reduced values of the
Homeostatic Model Assessment (HOMA)-IR [F(2, 15) = 8.44,
∗∗P < 0.01], defined as an index for insulin resistance, as well
as increased values of HOMA-β [F(2, 15) = 7.74,
∗∗P < 0.01],
defined as an index for beta-cell function, in the rats acutely and
repeatedly treated with URB597 (Table 1). In addition, leptin lev-
els were significantly reduced only in the plasma of the repeated
URB597-treated rats [F(2, 15) = 25.22,
∗∗∗P < 0.001]. No effects
were detected in the plasma levels of adiponectin and IGF-1 after
URB597 treatment (Table 1).
Effect of URB597 on Cell Proliferation in the
Subgranular Zone of the Dentate Gyrus, the
Hypothalamus and the Subventricular Zone of
the Lateral Ventricles
To investigate the impact of URB597 (0.3mg/kg) on cell pro-
liferation in relevant neurogenic zones of the adult brain, we
evaluated the number of newborn cells in the SGZ, hypotha-
lamus and SVZ by the analysis of the mitosis-related protein
phospho-histone H3 (Figure 2) and after the administration of
BrdU (50mg/kg) for 4 days (Figure 3). The number of phospho-
H3 and BrdU-ir cells was differentially detected depending on the
dose and the neurogenic zone analyzed. The number of phospho-
H3-ir cells was lower in the SGZ and hypothalamus after
repeated URB597 administration [F(2, 19) > 7.13,
∗P < 0.05]
(Figures 2A,B,D–I), but higher in the SVZ after acute URB597
administration [F(2, 21) = 4.24,
∗P < 0.05] (Figures 2C,J–L)
compared with the vehicle group. Equally, the number of BrdU-ir
cells was lower in the SGZ after repeated URB597 [F(2, 15) = 5.1,
∗P < 0.05] (Figures 3A,D–F) and higher in the SVZ after acute
URB597 [F(2, 15) = 4.43,
∗P < 0.05] (Figures 3C,J–L). Contrary
to phospho-H3, a significant increase in the number of BrdU-ir
cells was detected in the hypothalami of acute URB597-treated
rats [F(2, 15) = 15.21,
∗∗∗P < 0.001] (Figures 3B,G–I). More-
over, no change in the number of BrdU-ir cells was observed in
the hypothalami of repeated URB597-treated rats compared with
the vehicle group, but it was significantly reduced compared with
the acute URB597-treated rats [F(2,15) = 15.21,
##P < 0.01].
To determine the putative neuronal linage of these BrdU-ir
cells, we also evaluated the presence of their co-expression with
the neuron-specific β3-tubulin. As is shown in the representative
images of Figures 3M–V, we can observe some co-localization
of BrdU and neuron-specific β3-tubulin in a number of cells
in the SGZ (Figures 3M–O), hypothalamus (Figures 3P–R) and
SVZ (Figures 3S–V) of the three experimental groups. These data
indicate a neuronal linage of at least part of the newborn cells
after 5 days of BrdU treatment.
Effect of URB597 on Cell Survival in the
Hippocampus, Hypothalamus, Striatum, and
Olfactory Bulbs
To investigate the impact of URB597 on cell survival, we evalu-
ated the number of BrdU-ir cells in the hippocampus, hypothala-
mus, striatum and olfactory bulbs of rats sacrificed 3 weeks after
administering BrdU (Figure 4). The hippocampus, striatum and
olfactory bulbs of rats repeatedly treated with URB597 did not
show any difference in the number of BrdU-ir cells compared
with those of vehicle-treated rats (Figures 4A,C,D). However, we
observed a significant decrease in the number of BrdU-ir cells
specifically in the hypothalami of URB597-treated rats [F(1, 6) =
11.43, ∗∗P < 0.01] (Figure 4B).
To determine whether these BrdU-ir cells are neurons, we
analyzed their co-expression with the biomarker for mature
neurons NeuN (Figures 4M–T). We observed co-localization
of BrdU and NeuN in a number of cells in the hippocam-
pus (mainly in the granular cell layer) (Figures 4M,Q), striatum
(Figures 4O,S) and olfactory bulb (mainly in the internal plex-
iform and granule cell layers) (Figures 4P,T) of the two exper-
imental groups. In contrast, we could not detect BrdU/NeuN+
cells in the hypothalamic areas analyzed (Figures 4N,R).
Effect of URB597 on Astroglia in the
Hippocampus, Hypothalamus and Striatum
To investigate the impact of URB597 on astroglia, we evaluated
the intensity of GFAP immunoreactivity and the number of astro-
cytes that express GFAP in the hippocampus, hypothalamus and
striatum (Figure 5). The hippocampi and hypothalami of rats
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FIGURE 2 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on mitosis in the SGZ, hypothalamus and SVZ by
phospho-histone H3 immunohistochemistry. (A–C) The number of
positive cells is significantly lower in the SGZ and hypothalamus of
repeated URB597-treated rats, and significantly higher in the SVZ of
acute URB597-treated rats. (D–L) Representative microphotographs
showing low and high (insets) magnification views of the typical mitotic
cells expressing phospho-H3. The histograms represents the mean ±
s.e.m. per area (mm2) (n = 6–8) of the number of phospho-H3+ cells
per experimental group. ANOVA and Bonferroni’s test: *P < 0.05 vs.
vehicle group, #P < 0.05 vs. acute URB597 group. Scale bars are
included in each image.
acutely or repeatedly treated with URB597 showed an overall
decrease in the number of GFAP-ir cells compared with those
of vehicle-treated rats [Hippocampus, one-dose: F(2,21) = 12.89,
∗∗P < 0.01, 5-doses: ∗∗∗P < 0.001; Hypothalamus, one-dose:
F(2, 21) = 9.17,
∗∗P < 0.01, 5-doses: ∗P < 0.05] (Figures 5A,B).
Regarding the hippocampus, the reduction in the number of cells
expressing GFAP was significant in the dentate gyrus (∗∗∗P <
0.001), CA3 (∗∗P < 0.01) and CA1 (∗P < 0.05) fields. This
decrease in the number of GFAP-ir cells agrees with a lower
immunoreactivity of GFAP in both brain regions (Hippocam-
pus, acute and repeated URB597: ∗∗P < 0.01; Hypothalamus,
repeated URB597: ∗∗P < 0.01) (Figures 5D,E). It should be
noted that the decrease of GFAP immunoreactivity in the hip-
pocampus and hypothalamus after URB597 treatment can be
also attributed as a consequence of a reduction in the den-
sity of branched processes that characterize the labeled astro-
cytes (Figures 5G–L, insets). This effect contrasted with the
increase in the number of GFAP-ir cells and GFAP immunore-
activity observed in the striatum of acute URB597-treated rats
[F(2, 18) = 5.11,
∗P < 0.05] (Figures 5C,F,M–O). However, when
the treatment of URB597 was prolonged for 5 days, we could
not observe any change in the number of GFAP-ir cells or GFAP
immunoreactivity in the striatum.
Focusing on the SGZ of the dentate gyrus, we observed
the presence of some BrdU-ir cells that expressed GFAP
(Figures 5P–R) in the three experimental groups. These data can
suggest a glial linage of part of the newborn cells in the SGZ
after 5 days of BrdU treatment. We could not find co-localization
of BrdU and GFAP in cells of the hypothalamus and
striatum.
Effect of URB597 on Microglia in the
Hippocampus, Hypothalamus and Striatum
To investigate the impact of URB597 on microglia, we eval-
uated the number of microglial cells that express Iba1 in the
hippocampus, hypothalamus and striatum (Figure 6). The hip-
pocampus of rats acutely and repeatedly treated with URB597
showed an overall decrease in the number of cells express-
ing Iba1 compared with that of vehicle-treated rats [F(2, 17) =
7.12, ∗P < 0.05] (Figures 6A,D–F). Iba1-ir cells in the
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FIGURE 3 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on cell proliferation in the SGZ, hypothalamus and SVZ by
BrdU immunohistochemistry. (A–C) The number of positive cells is
significantly lower in the SGZ of repeated URB597-treated rats, and
significantly higher in the hypothalamus and SVZ of acute URB597-treated
rats. (D–L) Representative microphotographs showing low and high (insets)
magnification views of the typical clustering of newborn cells containing the
BrdU labeling. (M–V) Newborn cells in the SGZ, hypothalamus and SVZ
showing the co-localization of BrdU (green) and the neuron-specific
β3-tubulin (red) by confocal immunofluorescence. The histograms represents
the mean ± s.e.m. per area (mm2 ) (n = 6–8) of the number of BrdU+ cells
per experimental group. ANOVA and Bonferroni’s test: *P < 0.05,
***P < 0.001 vs. vehicle group, ##P < 0.01 vs. acute URB597 group. Scale
bars are included in each image.
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FIGURE 4 | Effects of repeated treatment of URB595 (0.3mg/kg)
on cell survival in the hippocampus, hypothalamus, striatum and
olfactory bulbs by BrdU immunohistochemistry. (A–D) The number
of positive cells is significantly lower in the hypothalamus of repeated
URB597-treated rats sacrificed 3 weeks after BrdU administration.
(E–L) Representative microphotographs showing low and high (insets)
magnification views of the typical clustering of BrdU-ir cells. (M–T)
Cells in the hippocampus, hypothalamus, striatum and olfactory bulbs
showing the co-localization of BrdU (green) and the biomarker for
mature neurons NeuN (red) by confocal immunofluorescence. The
histograms represents the mean ± s.e.m. per area (mm2 ) (n = 6–8) of
the number of BrdU+ cells per experimental group. ANOVA and
Bonferroni’s test: **P < 0.01 vs. vehicle group. Scale bars are included
in each image.
hippocampus of repeated URB597-treated rats also showed
an apparent reduction in the density of branched processes
that characterize the microglial cells (Figures 6D–F, insets).
On the contrary, no effect was observed in the hypothala-
mus and striatum of the acutely and repeatedly treated rats
(Figures 6B,C,G–L).
Effect of URB597 on Apoptotic Cells in the
Hippocampus, Hypothalamus, and Striatum
Apoptotic cells, as determined by cleaved caspase-3, were
assessed in the hippocampus, hypothalamus and striatum of rats
acutely and repeatedly treated with URB597 (Figure 7). Differ-
ences in the number of cleaved caspase-3-ir cells were detected
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FIGURE 5 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on astroglia in the SGZ, hypothalamus and SVZ by GFAP
immunohistochemistry. (A–F) The number of positive cells and the
intensity of GFAP immunoreactivity are significantly lower in the hippocampus
and hypothalamus of repeated URB597-treated rats, and significantly higher
in the striatum of acute URB597-treated rats. (G–O) Representative
microphotographs showing low and high (insets) magnification views of cells
expressing GFAP. (M–V) Newborn cells in the SGZ showing the
co-localization of BrdU (green) and the astrocyte-specific GFAP (red) by
confocal immunofluorescence. The histograms represents the mean ±
s.e.m. per area (mm2) (n = 6–8) of the number of GFAP+ cells per
experimental group. ANOVA and Bonferroni’s test: *P < 0.05, **P < 0.01,
***P < 0.001 vs. vehicle group, #P < 0.05, ###P < 0.001 vs. acute
URB597 group. Scale bars are included in each image.
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FIGURE 6 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on microglia in the SGZ, hypothalamus and SVZ by
Iba-1 immunohistochemistry. (A–C) The number of positive cells are
specifically lower in the hippocampus of acute and repeated
URB597-treated rats. (D–L) Representative microphotographs showing
low and high (insets) magnification views of cells expressing Iba-1. The
histograms represents the mean ± s.e.m. per area (mm2 ) (n = 6–8) of
the number of Iba1+ cells per experimental group. ANOVA and
Bonferroni’s test: *P < 0.05 vs. vehicle group. Scale bars are included in
each image.
depending on the dose and brais zone analyzed. The hippocam-
pus of rats treated with repeated URB597 showed an overall
decrease in the number of cleaved caspase-3-ir cells compared
with that of vehicle-treated rats [F(2, 19) = 21.31,
∗∗∗P < 0.001]
(Figures 7A,D–F). The decrease in the number of apoptotic cells
was significant in the dentate gyrus, CA3 (both at ∗∗P < 0.01)
and CA1 (∗P < 0.05), being especially relevant in those rats
acutely treated with URB597 (DG: ∗∗P < 0.01; CA3: ∗P < 0.05).
No changes in the number of cells expressing cleaved caspase-3
were observed in the hypothalamus (Figures 7B,G–I). Opposed
effects were observed in the striatum depending on the dose of
URB597 used (Figures 7C,J–L). Thus, as was described above
for BrdU and GFAP, we observed an increase in the number
of cleaved caspase-3-ir cells in the striatum of acute URB597-
treated rats compared with vehicle-treated rats [F(2, 20) = 12.17,
∗P < 0.05]. On the contrary, the striatum of the rats repeat-
edly treated with URB597 showed a decrease in the number
of cells expressing cleaved caspase-3 compared with that of the
rats treated with vehicle (∗P < 0.05) or after 5 days of the acute
URB597 (###P < 0.001) (Figures 7C,J–L).
Effect of URB597 on the Plasma Levels of
Endocannabinoids
To determine the endocannabinoid tone after the URB597 treat-
ment, we analyzed the levels of AEA, PEA, OEA, and 2-AG in the
plasma (Figure 8). As we expected, increased levels of AEA, PEA,
and OEA were exclusively observed in the plasma of repeated
URB597-treated rats compared with vehicle [F(2, 33) > 17.38,
∗∗∗P < 0.001] or acute URB597 (###P < 0.001)-treated rats
(Figure 8). Neither of the two administrations used for URB597
modified the plasma levels of 2-AG.
Effect of URB597 on the Gene and
Immunohistochemical Expression of FAAH and
CB1 Receptor in the Hippocampus,
Hypothalamus and Striatum
To assess whether the changes observed in the endocannabinoid
tone are in concordance with the expression of pertinent
components of the endocannabinoid system, we evaluated
the gene and protein (immunohistochemical) expression of
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FIGURE 7 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on apoptosis in the SGZ, hypothalamus and SVZ by
cleaved caspase-3 immunohistochemistry. (A–C) The number of
positive cells are significantly lower in the hippocampus and striatum of
repeated URB597-treated rats, and significantly higher in the striatum of
acute URB597-treated rats. (D–L) Representative microphotographs
showing low and high (insets) magnification views of cells expressing cleaved
caspase-3. The histograms represents the mean ± s.e.m. per area (mm2)
(n = 6–8) of the number of cleaved casp. 3+ cells per experimental group.
ANOVA and Bonferroni’s test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle
group, #P < 0.05, ###P < 0.001 vs. acute URB597 group. Scale bars are
included in each image.
the NAEs-hydrolyzing enzyme FAAH and the CB1 cannabi-
noid receptor in the hippocampus, hypothalamus and striatum
of rats after URB597 treatment (Figure 9). Rats repeat-
edly treated with URB597 showed decreases in both gene
and immunohistochemical expressions of FAAH and CB1
in the hippocampus (Figures 9A,D,G–I,P–R), FAAH in the
hypothalamus (Figures 9B,E,J–L) and CB1 in the striatum
(Figures 9C,F,V–X). In addition, we observed additional changes
in gene expression, which is not confirmed by the correspondent
immunohistochemical analysis, such as increased levels of Faah
mRNA in the striatum of acute and repeated URB597-treated rats
as well as the decrease in the hypothalamic levels of FaahmRNA
and the striatal levels of Cnr1 mRNA in acute URB597-treated
rats (Figures 9B,C).
Discussion
The biological activities associated to the NAEs OEA, PEA,
and AEA, including neural proliferation, cell survival and
neuroinflammation, require the control of their levels, for
instance through the NAEs hydrolyzing FAAH activity, and the
FIGURE 8 | Effects of acute and repeated treatment of URB595
(0.3mg/kg) on the plasma levels of AEA, PEA, OEA (A) and 2-AG (B).
The histograms represents the mean ± s.e.m. (n = 12) per experimental
group. ANOVA and Bonferroni’s test: ***P < 0.001 vs. vehicle group,
###P < 0.001 vs. acute URB597 group.
activation of their local targets, such as the cannabinoid, TRPV1
and PPARα receptors. Our results confirm that the selective
FAAH inhibitor URB597 administered at an effective dose of
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FIGURE 9 | Gene (A–C) and immunohistochemical (D–F)
expression of FAAH and CB1 receptor in the hippocampus,
hypothalamus and striatum of acute and repeated
URB597-treated rats. (G–X) Representative microphotographs
showing low and high (insets) magnification views of FAAH and CB1
receptor immunoreactivity in the hippocampus, hypothalamus and
striatum. The histograms represents the mean ± s.e.m. (n = 6–8)
per experimental group. ANOVA and Bonferroni’s test: *P < 0.05,
**P < 0.01 vs. vehicle group, #P < 0.05, ##P < 0.01 vs. acute
URB597 group.
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0.3mg/kg/day for 5 days increased the levels of OEA, PEA and
AEA in the rat plasma. Different effects on the local expression
of FAAH and CB1 receptor were observed depending on the
brain region analyzed. In these rats, FAAH expression was specif-
ically reduced in the hippocampus and hypothalamus, whereas
CB1 expression was specifically reduced in the hippocampus and
striatum. The experimental group of rats sacrificed 5 days after
the acute treatment with URB597 (one dose and 4-days resting)
was performed in order to analyze whether the effects of the acute
URB597 treatment were persistent or compensatory along time.
These rats showed reductions of the immunohistochemical or
gene expression of FAAH in the hippocampus and hypothala-
mus as well as a decrease of CB1 gene expression in the striatum.
In keeping to the decreased expression of FAAH obtained in the
brain of URB597-treated rats, previous studies showed that the
genetic deletion of faah gene in mice and the systemic admin-
istration of URB597 in rats elevated brain levels of AEA and
amplified the responses of this endogenous cannabinoid agonist
(Fegley et al., 2005; Piomelli et al., 2006). Thus, the brain of faah-
null mice showed an increase that ranged from 2 to 15-fold of
AEA levels, a 17-fold increase of OEA levels and a 8-fold increase
of PEA levels (Cravatt et al., 2001; Fegley et al., 2005). One i.p.
administration of URB597 at a dose of 0.3mg/kg produced a 1.3-
fold increase of AEA and 1.6-fold increase of OEA and PEA in
the mouse brain (Fegley et al., 2005). Our results indicate that
the repeated administration of URB597 for 5 days can produce
specific alterations in the local expression of CB1 receptor that
must be interpreted depending on the brain region analyzed. The
excess of plasma levels of AEA produced by the prolonged FAAH
inactivation, as a consequence of the repeated URB597 admin-
istration, can produce a saturating effect on the CB1 activity,
resulting in a reduction of the turnover of CB1 receptor expres-
sion. This effect can be accepted in those brain regions with high
expression of CB1 such as the hippocampus and striatum.
The present study indicate that the endocannabinoid system
can actively regulate cell proliferation in vivo, as the effect of
URB597 on the FAAH activity and expression were accompa-
nied with changes in neural proliferation in a neurogenic region-
dependent manner. Thus, the subgranular zone of the dentate
gyrus of repeated URB597-treated rats showed a reduction in
neural proliferation, as the number of phospho-H3+ and BrdU+
cells was decreased. These results in the hippocampus are not
consistent with the promotion of cell proliferation after the spe-
cific CB1 activation and the inhibition of cell proliferation after
CB1 and CB2 blockage observed in vitro and in vivo in the mouse
dentate gyrus (Aguado et al., 2005; Goncalves et al., 2008). This
discrepancy can be explained by (1) the down-expression of the
hippocampal CB1 receptors, and (2) the putative participation
of non-cannabinoid systems as a consequence of the activation
of additional AEA targets such as TRPV1 receptor and/or the
over-activation of OEA and PEA targets such as PPARα recep-
tors. In agreement with our results, it should be mentioned that
(a) TRPV1-null mice showed an improved neurogenesis in the
SGZ, but not in the SVZ, after spatial learning (unpublished
observations, dissertation by Stock K., 2012; see also Stock et al.,
2012); and (b) URB597 administered at full inhibition of spinal
FAAH may contribute at producing TRPV1-mediated analgesia
(Starowicz et al., 2013). On the contrary, the subventricular zone
of the lateral ventricles of acute URB597-treated rats showed an
increase of the neural proliferation, as the number of phospho-
H3+ and BrdU+ cells was augmented. The increased subventric-
ular cell proliferation is consistent with previous studies showing
a higher number of subventricular Ki67-positive cells in mice
treated with URB597 at a dose of 5mg/kg/day for 5 days and
a lower number of subventricular Ki67-positive cells in mice
treated with CB2 antagonists (Goncalves et al., 2008). Moreover,
Goncalves et al. (2008) also showed that the effect of URB597
on the increased cell proliferation in the mouse subventricular
zone was specifically blocked when mice were also treated with
the selective CB2 antagonist JTE-907.
The effects of repeated URB597 on the hypothalamus showed
a more complicated interpretation than those on the hippocam-
pus and striatum, as there is no previous information about
the role of NAEs in the hypothalamic neural proliferation. We
suggest that the specific decrease of FAAH expression in the
hypothalamus could be associated with a likely decrease in the
hypothalamic neural proliferation, as the number of phospho-
H3+ cells was reduced but not the number of BrdU+ cells in the
repeated URB597-treated rats. We suspect that it could be nec-
essary additional days of URB597 treatment and/or a prolonged
stimulation of non-cannabinoid targets such as TRPV1 or PPARα
receptors to observe a clear decline in the hypothalamic neural
proliferation. Considering this possibility, we evaluated the sur-
vived BrdU+ cells in rats sacrificed 3 weeks after administering
BrdU and URB597. Interestingly, we could detect a decrease in
the number of BrdU+ cells specifically in the hypothalamus, but
not the remaining brain areas analyzed, of the repeated URB597-
treated rats. In contrast to these data, the hypothalamus of the
rats sacrificed 5 days after the acute URB597 treatment showed a
residual increase in neural proliferation, as the number of BrdU+
cells was augmented but not the number of phospho-H3+ cells.
We suspect that the acute URB597 effect on the hypothalamic
neural proliferation was erased as a consequence of the four rest-
ing days after the treatment. Regarding these previous results,
we suggest that AEA-TRPV1 and OEA/PEA-PPARα signaling
could be relevant pathways to be considered when analyzing
neurogenesis in the adult brain.
Beside the likely association between the local expression of
FAAH and the adult neurogenic cell proliferation, we hypoth-
esized that processes related with neuroinflammation and neu-
roprotection can be primary influence by the plasma lev-
els of the endocannabinoids (Balvers et al., 2013). Thus, the
effects of URB597 on the plasma levels of AEA, OEA, and
PEA were accompanied with changes in the glia and apopto-
sis in a brain region-dependent manner. The hippocampus of
repeated URB597-treated rats showed a decrease in the num-
ber of cells expressing GFAP (astrocytes), Iba-1 (microglial cells)
and cleaved caspase-3 (apoptotic cells). A similar reduction in
glia and apoptosis was observed in the hippocampus of rats
sacrificed 5 days after the acute URB597 treatment. Regarding
the hypothalamic glia, we observed a reduction in the num-
ber of cells expressing GFAP but not Iba-1, suggesting a reduc-
tion of astrocytes but not microglial cells in the hypothala-
mus of rats acutely and repeatedly treated with URB597. These
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results indicate that URB597 treatment likely showed an anti-
inflammatory profile, being evident in the hippocampus and
hypothalamus, which can be attributed to the high levels of
PEA in the plasma. URB597 and, specifically, PEA play an
important role in neuroinflammation propagation, as they can
attenuate microglia activation and migration by interacting with
cannabinoid-like receptors (Muccioli and Stella, 2008; Murphy
et al., 2012). On the contrary, the striatum of acute URB597-
treated rats showed an increase in the number of cells express-
ing GFAP (astrocytes) and cleaved caspase-3 (apoptotic cells).
This opposite effect in the striatum can be produced as a conse-
quence of a compensatory effect during the resting days after the
treatment.
It should be also noted a negative energy balance in rats
repeatedly treated with URB597, as we observed a transitory
reduction of body weight that was accompanied with a decrease
in the plasma levels of the basal glucose, tryglicerides, cholesterol,
leptin, and insulin. Despite the fact that no long-term modifi-
cation in cumulative food intake was detected in these rats, the
amelioration of these metabolic parameters agrees with the cen-
tral effect of feeding-controlled signals. Thus, the increased levels
of OEA can produce anorexic effects by activating satiety signals
in the hypothalamus (Fu et al., 2003; Lo Verme et al., 2005a)
and could be related with a reduced number of hypothalamic
proliferating cells.
As summary, the repeated administration of URB597
increased the plasma levels of AEA, OEA, and PEA, and pro-
duced decreased expression of FAAH and CB1 receptor in the
hippocampus, hypothalamus and striatum. This endocannabi-
noid tone, as a consequence of the URB597 treatment, is cou-
pled to a decrease in neurogenic cell proliferation, cell survival
and glia, mainly focalized in the hippocampus and hypothala-
mus, as well as a reduced apoptosis in the hippocampus and
striatum. In contrast, one dose/4-days resting of URB597 treat-
ment produced opposed effects specifically observed in the stria-
tum. These changes in the brain were associated with a negative
energy balance as a transitory body weight decrease and reduced
plasma levels of glucose, triglycerides and cholesterol were
observed.
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